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Siddharth Sridhar1, Jasper Fuk-Woo Chan1,2,3 and Kwok-Yung Yuen1,2,3*Abstract
Background: Neuromyelitis optica (NMO) is an autoimmune inflammatory condition of the central nervous system
that is characterized by circulating anti-aquaporin-4 antibodies, transverse myelitis and optic neuritis. NMO spectrum
disorders are rarely reported in patients with active pulmonary tuberculosis (TB). We report a fatal case of
anti-aquaporin-4 antibody positive NMO spectrum disorder in a patient who was receiving treatment for pulmonary
tuberculosis.
Case presentation: A previously healthy 42-year-old Chinese man was diagnosed with smear positive pulmonary
tuberculosis. After one month of anti-tuberculosis treatment, he presented with acute generalized weakness and
rapid neurological deterioration. Spinal imaging and anti-aquaporin-4 antibody positivity established a diagnosis of
neuromyelitis optica spectrum disorder.
Conclusion: This is the first reported case of anti-aquaporin-4 antibody-positive NMO spectrum disorder in a patient
with active tuberculosis. It shows the usefulness of testing for anti-aquaporin-4 antibodies while evaluating
neurological deterioration in patients with tuberculosis. The literature on the rare association between NMO
spectrum disorders and TB is reviewed.
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Neuromyelitis optica is an autoimmune inflammatory
disorder of the central nervous system affecting the optic
nerves and the spinal cord, manifesting as recurrent epi-
sodes of longitudinally extensive transverse myelitis
(LETM) and/or optic neuritis. Previously classified as a
subtype of multiple sclerosis, NMO is now considered to
be a distinct clinical, pathological, and immunological
entity [1]. A key diagnostic test for NMO spectrum disor-
ders is the presence of anti-aquaporin-4 (anti-Aqp-4) IgG
antibodies in patient serum [2]. Aquaporin-4 is a mem-
brane water channel that is most abundant at astrocytic
end-feet. Anti-Aqp-4 IgG has been found to be a highly
specific marker for the NMO spectrum disorders that in-
clude classic NMO, isolated optic neuritis, isolated LETM,* Correspondence: kyyuen@hku.hk
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unless otherwise stated.and isolated brain stem encephalitis [3-6]. This test now
forms part of the diagnostic criteria for neuromyelitis
optica [2].
A small number of case reports describe patients devel-
oping NMO like syndromes shortly after being diagnosed
with pulmonary tuberculosis, hinting at a rare association
between the two entities [7-9]. Despite the shortcomings
of case–control studies in elucidating rare associations be-
tween exposures and disease, two groups have conducted
case–control studies comparing the prevalence of TB
between NMO patients and control patients with other
neurological diagnoses. While one study found a sig-
nificant association between NMO and TB in a high
TB – low NMO prevalence setting in South Africa, an-
other study in an intermediate TB – high NMO preva-
lence setting in southern China failed to demonstrate a
significant association [10,11]. However, a clinical trial
conducted in another Chinese NMO patient group dem-
onstrated a marked beneficial effect of anti-TB treatment
on the course of patients with steroid refractory NMO
even in the absence of overt tuberculosis suggesting a pos-
sible association of latent TB with NMO that would haveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the evidence to date is in favor of an association with TB
in a subset of NMO patients, who may benefit from anti-
TB treatment. None of the patients with TB associated
NMO-like disorder described previously have been shown
to have anti-Aqp-4 antibodies.
We report a rapidly progressive and fatal case of anti-
Aqp-4 antibody-positive neuromyelitis optica (NMO) like
disorder in a patient receiving treatment for pulmonary
TB. To the best of our knowledge, our case is the first
report of anti-Aqp-4 antibody-positive NMO like disorder
in a patient with active pulmonary TB. The rapidity of our
patient’s deterioration is also unprecedented in the pub-
lished literature on TB-associated NMO.
From our case report and other cases in the literature,
NMO appears to develop shortly after the diagnosis of
pulmonary TB even when the patient is started on appro-
priate anti-TB medications. We show that anti-Aqp-4
antibodies are present in TB associated NMO; these anti-
bodies are known to play a pathogenic role in NMO [2].
The mechanism by which TB infection triggers the forma-
tion of these antibodies is uncertain. Mycobacterium
tuberculosis surface antigens may trigger the formation
of cross-reactive antibodies against aquaporin-4 channel
proteins. However, immunity against active TB infection
is generally geared towards a cell-mediated immune re-
sponse rather than a humoral response, therefore the
contribution of this mechanism is uncertain. Further re-
search is required to elucidate the biological basis for
this association.
In summary, this case highlights NMO like disorder as a
fatal immunological complication of TB and illustrates theFigure 1 Radiological imaging of lung and spinal cord. a: Chest X-ray (
consolidation with left upper zone predominance. b: Sagittal section of MR
levels of the spinal cord suggestive of longitudinally extensive transverse mdiagnostic role of anti-Aqp-4-antibody in patients with
active TB and concomitant neurological deterioration.
Case presentation
A previously healthy 42-year-old man presented with
cough and fever for three weeks. Chest radiograph on
admission revealed bilateral consolidations with predom-
inant upper zone involvement (Figure 1a). Blood tests
showed normal total white cell count (5.99×109/l), but
marked lymphopenia (0.20×109/l). Ziehl-Neelsen-stained
smear of the sputum revealed >1 acid-fast bacillus (AFB)
per oil-immersion field, suggestive of pulmonary tuber-
culosis (TB). The patient was started on oral isoniazid
300 mg daily, rifampicin 450 mg daily, ethambutol
700 mg daily, pyrazinamide 1250 mg daily, and pyridox-
ine 10 mg daily. His condition improved with good drug
compliance under directly observed treatment in an out-
patient setting. Sputum cultures on Lowenstein-Jensen
and Stonebrink media were positive for Mycobacterium
tuberculosis. The patient was readmitted after four weeks
of treatment with generalized weakness. Physical exam-
ination showed weakness of MRC grade two over all
four limbs. He was hyporeflexic and plantar responses
were equivocal. He had a palpable bladder and lax anal
tone. Cranial nerve examination was unremarkable.
Blood tests showed leukocytosis with neutrophilia and
lymphopenia (total white cell, 13.11×109/l; neutrophils,
11.17×109/l; lymphocytes, 0.49×109/l). Chest radiograph
showed worsened bilateral apical lung infiltrates. A mag-
netic resonance imaging (MRI) scan of the spine was
performed urgently and revealed diffuse intramedullary
T2-weighted hyperintensity of the spine from C1 to T4PA Erect film) on initial presentation showing bilateral lung field patchy
I spine showing diffuse T2-weighted hyperintensity involving C1-T4
yelitis (LETM).
Sridhar et al. BMC Infectious Diseases 2014, 14:470 Page 3 of 4
http://www.biomedcentral.com/1471-2334/14/470levels and from T4 to the conus terminalis, suggestive
of longitudinally extensive transverse myelitis (LETM)
(Figure 1b). Diffuse consolidation of bilateral lung apices
and a cavitating lesion with air-fluid level at the left lung
apex were noted. Ziehl-Neelsen-stained smear of the
endotracheal aspirate showed >1 AFB/oil immersion
field, confirming treatment failure despite four weeks
of first-line anti-tuberculous treatment.
The patient’s condition deteriorated rapidly with high
fever, hypotension, and coma. He was intubated and
vasopressor support was commenced. A plain computed
tomography scan of the brain was unremarkable. Lum-
bar puncture showed clear cerebrospinal fluid (CSF)
with an elevated opening pressure of 20 cmH2O. Total
cell count of the CSF was elevated to 62×106/l with neu-
trophil predominance. CSF and peripheral blood glucose
levels were 1.1 mmol/l and 4.9 mmol/l respectively, and
CSF protein was elevated to >6 mmol/l. Gram-stained and
Ziehl-Neelsen-stained smears of the CSF showed no organ-
ism. Culture of the CSF yielded no bacterial, mycobacterial,
and fungal growth. Molecular tests including TB-PCR,
HSV-PCR, and enterovirus RT-PCR were negative.
A diagnosis of disseminated TB with central nervous
system involvement was made. As the patient’s condi-
tion had deteriorated despite four weeks of first line
anti-tuberculous drugs, multidrug-resistant TB was sus-
pected. The drug regimen was changed to intravenous
rifampicin 450 mg q24 h, ethambutol 1200 mg q24 h,
levofloxacin 500 mg q24 h, linezolid 600 mg q24 h, and
amikacin 750 mg q24 h. The patient was also given a
combination of intravenous meropenem 1000 mg q8 h
and intravenous amoxicillin-clavulanate 1200 mg q12 h
for broad-spectrum antibacterial and anti-tuberculous
coverage [13,14]. Intravenous dexamethasone was also
started at 4 mg q8 h [15]. Genotypic testing for drug re-
sistance using a line probe assay (GenoType MTBDRplus,
Hain Lifescience) on the M. tuberculosis isolate from the
patient’s first admission was negative for the common iso-
niazid and rifampicin resistance mutations (katG, inhA
and rpoB respectively). An underlying immunological de-
fect was considered in view of the clinical deterioration
despite in-vitro drug susceptibility. The combined HIV-
antigen/antibody test and anti-interferon-gamma auto-
antibody were negative [16,17].
Due to the radiological finding of LETM, the neuromy-
elitis optica (NMO) spectrum disorders were a diagnostic
consideration. Serum anti-aquaporin-4 (anti-Aqp-4) anti-
bodies were positive by an immunofluorescence assay
(Euroimmun). The patient was diagnosed with NMO
spectrum disorder complicating active pulmonary TB
without evidence of mycobacterial central nervous system
infection. Despite treatment with corticosteroid, the pa-
tient’s condition further deteriorated with severe hyper-
thermia, high ventilatory requirement, loss of brainstemreflexes, and labile hemodynamic status. He died after
thirteen days of admission.
Conclusion
In summary, our case highlights NMO like disorders as
an important diagnostic consideration in patients with
active TB who present with acute neurological disorders.
Serum anti-Aqp-4 antibodies should be part of the diag-
nostic workup of patients with active TB who present with
transverse myelitis and/or optic neuritis. Further multi-
center trials are required to clarify the etiological role of
TB in triggering NMO like disorders.
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